Key Points {#FPar1}
==========

A whole-body physiologically based pharmacokinetic (PBPK) model of elagolix was developed to quantitatively account for the contribution of metabolizing enzymes, transporters, and their interplay.The PBPK model was able to adequately describe clinical pharmacokinetics data and recover the observed drug--drug interaction (DDI), demonstrating that the model is verified for the intended purpose.Simulations using elagolix PBPK model informed labeling information regarding the DDI potential with digoxin (P-glycoprotein substrate) and midazolam (cytochrome P450 3A4 substrate) under dosing conditions that were not tested clinically.

Introduction {#Sec1}
============

Elagolix is a non-peptide, oral gonadotropin-releasing hormone (GnRH) receptor antagonist recently approved for the management of moderate to severe pain associated with endometriosis. Elagolix inhibition of GnRH receptors at the anterior pituitary level causes a rapid decrease in secretion of the gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a dose-dependent decrease in the ovarian production of estradiol and other sex hormones, with partial suppression at lower doses of elagolix, to nearly full suppression with higher doses \[[@CR1]\]. The phase III clinical studies of elagolix demonstrated that elagolix 150 mg once daily (QD) and 200 mg twice daily (BID) produce clinically meaningful pain reduction, including dysmenorrhea and non-menstrual pelvic pain in premenopausal women with moderate to severe endometriosis-associated pain \[[@CR2]\].

Elagolix is rapidly absorbed upon oral administration, with maximum plasma concentration (*C*~max~) occurring 1 h after dosing. Elagolix exposures \[*C*~max~ and area under the concentration--time curve (AUC)\] increase dose proportionally at the clinical doses of 150 mg QD and 200 mg BID, with an apparent terminal elimination half-life (t~½~) of approximately 4--6 h \[[@CR3]\]. The contribution of the drug-metabolizing enzyme cytochrome P450 (CYP) 3A, efflux transporter P-glycoprotein (P-gp), and uptake transporter organic anion transporting polypeptide (OATP) 1B1/1B3 to the disposition of elagolix has been quantified based on mechanistic drug--drug interaction (DDI) studies of elagolix with ketoconazole (a strong inhibitor of CYP3A/P-gp) and rifampin (a CYP3A and P-gp inducer and OATP1B1/1B3 inhibitor) \[[@CR4]\]. Following the coadministration of ketoconazole 400 mg with elagolix 150 mg, the elagolix AUC increased 2.2-fold, indicating that elagolix is not a sensitive substrate of CYP3A4. Following a single dose of rifampin 600 mg coadministered with elagolix 150 mg, the elagolix AUC increased 4.6-fold, while multiple doses of rifampin increased the elagolix AUC by 1.65-fold. The increase in elagolix exposures after single dosing may be attributable to OATP1B1 inhibition, while the decreased magnitude of the interaction of elagolix with multiple doses of rifampin are likely due to the net effect resulting from acute OATP1B1 inhibition and CYP3A/P-gp induction. Given that hepatic elimination is an important mechanism in the overall clearance of elagolix, hepatic impairment (HI) was associated with increased elagolix exposures in Child--Pugh B (AUC ratio 2.7) and Child--Pugh C (AUC ratio 6.7) patients compared with healthy volunteers. There was no impact on elagolix exposures in Child--Pugh A patients \[[@CR5]\].

As a perpetrator, elagolix 150 mg QD induced CYP3A based on the observed 35% decrease in midazolam AUC, and at 200 mg BID inhibited P-gp based on the observed approximately 70% and 30% increases in digoxin *C*~max~ and AUC, respectively. However, the effect of elagolix as a CYP3A inducer at a 200 mg BID dose and as a P-gp inhibitor at a 150 mg QD dose was not evaluated in clinical DDI studies \[[@CR6], [@CR7]\].

Physiologically based pharmacokinetic (PBPK) modeling is a powerful approach being used to predict the magnitude of DDI potential and is accepted by drug regulatory agencies \[[@CR8], [@CR9]\]. The application of PBPK to inform dosing recommendations and assessment of DDI in regulatory submissions is a fundamental part of the model-informed drug development paradigm. PBPK models that have been verified with clinical data have been increasingly used to predict the DDI potential for untested scenarios \[[@CR10], [@CR11]\]. Given the regulatory acceptance and demonstrated scientific robustness of the PBPK approach, a PBPK model of elagolix was developed and verified to inform the DDI potential of elagolix in support of labeling recommendations.

Thus, the aim of the current analysis was to (1) develop and verify a whole-body PBPK model of elagolix that described the interplay between metabolism by CYP3A4, and hepatic uptake by OATP1B1, using clinical data from phase I PK single and multiple ascending doses, DDIs, and special populations studies of elagolix; and (2) predict the DDI potential of elagolix as a P-gp and CYP3A modulator at clinically relevant doses that were not evaluated in clinical DDI studies.

Materials and Methods {#Sec2}
=====================

The SimCYP^®^ (V15.0.86.0; Certara, Sheffield, UK) population-based absorption, distribution, metabolism, and excretion (ADME) simulator was used for the PBPK model development, verification, and application. The PBPK model of elagolix was developed using a combined bottom-up and top-down modeling approach \[[@CR12]\]. The base model of elagolix was developed using the in vitro parameters, while the PK and DDI data from multiple clinical studies were used to optimize the contribution of each pathway involved in the ADME of elagolix. The final model parameters and their sources are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Input parameters of the elagolix PBPK model using SimCYP (V15.0.86.0)ParameterParameter value used in the SimCYP modelSourcePhysiochemical and blood binding Molecular weight (g/mol)631.6Experimental data logP1.34 pK~a~ 14 pK~a~ 27.9 Blood-to-plasma ratio0.62 *f*~u~0.21Absorption modelADAM Peff,man typeRegional P Caco-2 (10^−6^ cm/s)10Estimated based on clinical data Input formSolutionExperimental dataDistribution modelFull PBPK model *V*~ss~ input typePredicted using Method 2SimCYP predictedElimination CYP3A4 CL~int~ (µL/min/pmol of isoform)0.3Estimated based on clinical data CYP2C8 CL~int~ (µL/min/pmol of isoform)0.029Experimental data CYP2D6 CL~int~ (µL/min/pmol of isoform)0.7Experimental data CL~renal~ (L/h)1.6Estimated based on clinical data Additional systemic CL/F (L/h)9Estimated based on clinical dataTransporter kinetics P-gp  CL~int~ (µL/min/pmol)4Estimated based on clinical data OATP1B1  *J*~max~ (pmol/min/million cells)215Estimated based on clinical data  *K*~m~ (µM)0.66Experimental dataPerpetrator properties CYP3A4 enzyme MBI  MBI K~app~ (µM)74Experimental data  MBI K~inact~ (1/h)0.019Experimental data CYP3A4 enzyme induction  Ind~max~20Experimental data  Ind EC~50~ (µM)2Estimated based on clinical data P-gp inhibition K~i~ (µM)0.5Estimated based on clinical data*ADAM* advanced dissolution, absorption, and metabolism, *CL/F* apparent clearance, *CL*~*int*~ intrinsic clearance, *CL*~*renal*~ renal clearance, *CYP* cytochrome P450, *EC*~*50*~ half maximal effective concentration, *fu* fraction of unbound drug in plasma, *Ind*~*max*~ maximum induction, *J*~*max*~ maximal transport velocity, *K*~*app*~ apparent binding constant, *K*~*i*~ inhibitory constant, *K*~*inact*~ inactivation rate constant, *K*~*m*~ Michaelis--Menten constant, *logP* partition coefficient, *MBI* mechanism-based inactivation, *OATP* organic anion transporting polypeptide, *PBPK* physiologically based pharmacokinetic, *P-gp* P-glycoprotein, *PK* pharmacokinetic, *pKa* acid dissociation constant, *V*~*ss*~ volume of distribution at steady state

Elagolix Physiologically Based Pharmacokinetic (PBPK) Model Development, Verification, and Application {#Sec3}
------------------------------------------------------------------------------------------------------

SimCYP^®^ library model files of ketoconazole, rifampin, midazolam, and digoxin were used during the elagolix PBPK model development to assign contributions of various disposition mechanisms. No modifications were made to these model files, except for rifampin, as described in Sect. [2.2](#Sec4){ref-type="sec"}, to capture the induction of P-gp following multiple dosing of rifampin. Figure [1](#Fig1){ref-type="fig"} provides an overview of the strategy used for the elagolix PBPK model development, verification, and application. The base PBPK model of elagolix was initially developed using physicochemical and in vitro data (Table [1](#Tab1){ref-type="table"}). The absorption of elagolix was captured using the mechanistic advanced dissolution, absorption, and metabolism (ADAM) model in SimCYP^®^ \[[@CR23]\]. The ADAM model was selected to capture the intestinal absorption, metabolism, and efflux of elagolix via CYP3A4 and P-gp. Parameters for the ADAM model were based on built-in predictive in silico tools within the simulator, in vitro permeability Caco-2 data, or were optimized based on clinical PK data (Table [1](#Tab1){ref-type="table"}). Since elagolix is a substrate of the hepatic uptake transporter OATP1B1, a whole-body PBPK model functionality was used to capture the hepatic uptake transport kinetics in SimCYP^®^ to describe the PK profile of elagolix in healthy volunteers. The apparent volume of distribution at steady state (*V*~ss~) was estimated using the method published by Rodgers and Rowland (Method 2 in SimCYP^®^) \[[@CR13]\]. Since elagolix is actively transported into the hepatocyte via the uptake transporter OATP1B1, distribution to the liver was described by a permeability-limited model. The contribution of OATP1B1 to the overall uptake was estimated using in vitro and clinical data from a DDI study with a single dose of rifampin (inhibitor of the OATP1B1 transporter) \[[@CR4]\]. The elagolix--rifampin DDI data were used to optimize the in vitro maximal transport velocity (*J*~max~) parameter for OATP1B1. Sensitivity analysis (electronic supplementary Fig. 1) was conducted to refine the final*J*~max~ estimate to improve the predictive performance of the PBPK model for the elagolix DDI with rifampin. The contribution of CYP3A4 to the overall elimination of elagolix was optimized using data from a multiple-dose rifampin DDI study \[[@CR3]\]. The CYP3A4 intrinsic clearance (CL~int~) estimate that helped improve the predictive performance of the PBPK model for the elagolix--rifampin DDI (following multiple doses) study was identified as the final parameter estimate in the model. At this step, verification of the model was conducted according to Shebley et al., defined as establishing consistency between the input parameters and underlying mechanisms and assumptions, and the ability of the model to successfully simulate independent sets of observed data \[[@CR11]\]. The CYP3A4 contribution was verified using clinical data from the ketoconazole--elagolix DDI study by conducting sensitivity analysis (electronic supplementary Fig. 2). The overall hepatic metabolism of elagolix in the model was verified by comparing the model-predicted impact of HI on elagolix exposures with clinical data in the HI population.Fig. 1Overview of the physiologically based pharmacokinetic model development, verification, and application strategy

As a perpetrator, elagolix inhibits P-gp and induces CYP3A4. The perpetrator (or interaction) model of elagolix was optimized (Table [1](#Tab1){ref-type="table"}) using clinical data from DDI studies with digoxin (P-gp substrate) and midazolam (CYP3A substrate) \[[@CR3]\]. To improve the predictive performance of the PBPK model, the in vitro induction parameter (half maximal effective concentration \[EC~50~\]) for elagolix was optimized using the clinical DDI study of elagolix with midazolam. Similarly, the digoxin--elagolix DDI study was used to optimize the in vitro P-gp inhibition (inhibitory constant \[K~i~\]) parameter.

Simulation Design {#Sec4}
-----------------

All simulations were performed using the default SimCYP^®^ virtual Sim-Healthy Population representative (electronic supplementary Table 1). For all simulations, the physiological parameters for a healthy population were the same as reported by SimCYP^®^ (version 15.0.86.0). For the HI study, the HI population model files (Child--Pugh A, B, and C) in SimCYP^®^ were used. All population files were used without any modifications.

The expression of P-gp was the only physiological parameter that was altered for the elagolix--rifampin DDI simulations. Rifampin has been reported to induce P-gp expression four folds in in vitro and clinical studies \[[@CR14], [@CR15]\]. The four folds induction is known to predict digoxin DDIs \[[@CR16]\], and hence P-gp expression in the liver and the intestine was increased four folds on day 10 of the rifampin--elagolix DDI study using the methodology reported by Neuhoff et al. \[[@CR16]\]. Following incorporation of the four folds increase in P-gp expression, the model-predicted digoxin *C*~max~ ratio was compared with the observed clinical data (electronic supplementary Fig. 3).

The study design used for the simulations was similar to the reported clinical study designs with regard to dose, route of administration, study duration, and fasting conditions (electronic supplementary Table [2](#Tab2){ref-type="table"}).Table 2Elagolix PBPK model development: predicted vs. observed pharmacokinetic parameters of elagolix following multiple doses in healthy subjectsPharmacokinetic parameter (units)150 mg QD (*N* = 6)200 mg BID (*N* = 7)PredictedObserved%PEPredictedObserved%PE*Day 1C*~max~ (ng/mL)5245073.47797129.4T~max~ (h)0.951.326.90.951.05.0AUC~τ~ (ng●h/mL)^a^132113310.8175618133.1*Day 21C*~max~ (ng/mL)5245743.468077412.1AUC~τ~ (ng●h/mL)^a^121312926.11518172512CL/F (L/h)12412311321448t~½~ (h)4.576.4228.84.544.295.8*AUC*~*τ*~ area under the curve over the dosing interval, *bid* twice daily, *C*~max~ maximum concentration, *PBPK* physiologically based pharmacokinetic, *%PE* percentage prediction error, *qd* once daily, *T*~*max*~ time to maximum concentration, *t*~*½*~ terminal elimination half-life

PBPK Model Performance Evaluation {#Sec5}
---------------------------------

### Prespecified Acceptance Criteria for Pharmacokinetic Parameters (Maximum Concentration \[*C*~max~\], Area Under the Concentration--Time Curve \[AUC\], and Half-Life) {#Sec6}

The ability of the PBPK model to predict the observed clinical data of phase I PK studies was evaluated and quantified based on the percentage prediction error (%PE). Predefined rules for acceptable %PE were set, and the model was optimized during model development until the %PE criteria were met. The %PE was calculated using the formula described below (Eq. [1](#Equ1){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{\% PE}} = \frac{{\left( {{\text{predicted mean}} - {\text{observed mean}}} \right)}}{\text{observed mean}} \times 100$$\end{document}$$

Based on the publication by Abduljalil et al. \[[@CR17]\], the elagolix model predicted PK parameters were deemed to be within the acceptable limit of prediction if the %PE was ≤ 50%.

### Prespecified Acceptance Criteria for Drug--Drug Interaction (DDI) Studies and Hepatic Impairment Studies (*C*~max~ Ratio and AUC Ratio) {#Sec7}

The model acceptance criterion for DDI studies was based on the publication by Guest et al. \[[@CR18]\] A variable prediction margin dependent on the observed magnitude of DDIs was used for assessing the success of model prediction. The model was deemed to be acceptable if the predicted *C*~max~ and AUC ratios were within the defined range of success criteria. The limits for *C*~max~ and AUC ratios were calculated using the formula below (Eq. [2](#Equ2){ref-type=""}).$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Limit}} = \frac{{1 + 2\left( {R_{\text{obs}} - 1} \right)}}{{R_{\text{obs}} }}$$\end{document}$$where *R*~obs~ = observed DDI ratio and is \> 1. For induction: *R*~obs~ = 1/(observed DDI ratio), Upper limit for acceptance = *R*~obs~ × Limit, Lower limit of acceptance = *R*~obs~/Limit

Results {#Sec8}
=======

Development and Verification of the Elagolix PBPK Model Using a Combined Bottom-Up and Top-Down Approach {#Sec9}
--------------------------------------------------------------------------------------------------------

The PBPK model of elagolix was developed using in vitro and clinical data. The PBPK model was able to adequately describe the PK profile (Fig. [2](#Fig2){ref-type="fig"}) and parameters (Table [2](#Tab2){ref-type="table"}) of elagolix following doses of 150 mg QD and 200 mg BID (%PE \< 12%). The contribution of OATP1B1 in the uptake of elagolix was optimized using the single-dose rifampin DDI study with elagolix \[[@CR19]\]. Following model optimization, the concentration--time profiles with and without rifampin were well described by the model both visually (Fig. [2](#Fig2){ref-type="fig"}a) and quantitatively (Fig. [2](#Fig2){ref-type="fig"}b). The simulated elagolix *C*~max~ and AUC ratios were 3.2 and 4.0, respectively, on day 1 of rifampin coadministration (Table [3](#Tab3){ref-type="table"}). While the predicted *C*~max~ and AUC ratios were within the predefined acceptance criterion, 28% underprediction by the model was observed. The CYP3A4 and P-gp contributions were optimized using clinical data from the administration of elagolix 150 mg with multiple doses of rifampin 600 mg QD \[[@CR19]\]. The model-simulated *C*~max~ and AUC ratios on day 10 were 2.28 and 2.29, respectively, and matched the observed *C*~max~ and AUC ratios of 2.0 and 1.65, respectively (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}).Fig. 2PBPK model development. **a** Predicted vs. observed mean concentration--time profiles of elagolix (150 mg QD) with and without coadministration of rifampin (600 mg QD). **b** Predicted vs. observed concentrations of elagolix from multiple-dose PK and DDI studies. *DDI* drug--drug interaction, *PBPK* physiologically based pharmacokinetic, *PK* pharmacokinetic, *QD* once dailyTable 3Elagolix PBPK model development and verification: predicted vs. observed ***C***~**max**~ and AUC ratios following coadministration of elagolix with prototypical perpetrators and in patients with hepatic impairmentElagolix dose, mgMean *C*~max~ ratioMean AUC ratioPredictedObserved%PEPredictedObserved%PECoadministered drug with elagolixDDI studies Rifampin day 1150^a^3.204.37274.005.58^b^28 Rifampin day 10150^a^2.282.00142.291.65^b^39 Ketoconazole150^a^2.011.77142.132.20^c^3.2Patient populationHepatic impairment studies Child--Pugh A150^a^1.50.8881.60.8^c^100 Child--Pugh B150^a^3.72.6424.52.7^c^67 Child--Pugh C150^a^4.86.2− 237.36.7^c^9*AUC* area under the curve, *AUC*~*24*~ AUC from time zero to 24 h, *AUC*~*∞*~ AUC from time zero to infinity, *C*~max~ maximum concentration, *DDI* drug--drug interaction, *PBPK* physiologically based pharmacokinetic,  *%PE* percentage prediction error (acceptance criteria)^a^Single-dose elagolix^b^AUC~24~^c^AUC~∞~

The contribution of the CYP3A4 and P-gp pathway in the overall disposition of elagolix was verified independently using the DDI study with ketoconazole \[[@CR19]\]. The model-simulated *C*~max~ and AUC ratios of elagolix were 2.01 and 2.13, respectively, and the observed *C*~max~ and AUC ratios were 1.77 and 2.2, respectively (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}a). The observed and predicted ratios were within the limits of the model acceptance criterion (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}).Fig. 3**a** PBPK model verification (elagolix as victim): predicted vs. observed mean concentration--time profiles of elagolix with and without coadministration of ketoconazole. **b** PBPK model verification: predicted vs. observed concentrations of elagolix from single-dose, DDI, and hepatic impairment studies. *DDI* drug--drug interaction, *PBPK* physiologically based pharmacokineticFig. 4PBPK model performance: observed and predicted *C*~max~ and AUC ratio for elagolix DDI studies fall within the predefined limits of model acceptance criteria. *AUC* area under the concentration--time curve, *C*~max~ maximum concentration, *DDI* drug--drug interaction, *PBPK* physiologically based pharmacokinetic

The assignment of hepatic metabolism to overall clearance of elagolix in the PBPK model was verified using clinical data from the HI studies. Based on the PBPK model simulations, the predicted ratio of elagolix AUC in Child--Pugh A, B, and C patients relative to healthy volunteers was 1.6, 4.5, and 7.3, respectively, while the clinically observed AUC ratios were 0.8, 2.7, and 6.7, respectively (Table [3](#Tab3){ref-type="table"}). For *C*~max~, the model-predicted ratios in Child--Pugh A, B, and C patients relative to healthy volunteers were 1.5, 3.7, and 4.8, respectively, while the clinically observed *C*~max~ ratios were 0.8, 2.6, and 6.2, respectively (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}b). The final PBPK model of elagolix as a victim reasonably captured the interplay between CYP3A4, P-gp, and OATP1B1 based on comparisons of the model simulation results with clinically observed PK, DDI ratios, and impact of HI. At this stage, the elagolix PBPK victim model was qualified for evaluation of the impact of extrinsic factors on modulation of multiple ADME mechanisms involved in the disposition of elagolix (Fig. [4](#Fig4){ref-type="fig"}).

PBPK Model of Elagolix as a Cytochrome P450 (CYP) 3A Inducer and P-Glygoprotein (P-gp) Inhibitor {#Sec10}
------------------------------------------------------------------------------------------------

The in vitro CYP3A induction data of elagolix, when used in the PBPK model, was not able to quantitatively predict the observed *C*~max~ and AUC ratios of midazolam (results not shown). To improve the predictive performance of the PBPK model, the in vitro induction parameter (EC~50~) for elagolix was optimized by approximately threefold. Following optimization, the model-predicted AUC ratio of 0.69 closely matched the observed AUC ratio of 0.65 (Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Similarly, for the digoxin--elagolix DDI study, the in vitro P-gp inhibition (*K*~i~) parameter of elagolix was optimized. Digoxin day 1 and day 10 simulated *C*~max~ ratios were 1.74 and 1.73, respectively, and the AUC ratios were 1.22 and 1.19, respectively. These model results were in good agreement with the observed day 1 and day 10 *C*~max~ ratios (1.73 and 1.71) and the day 1 and day 10 AUC ratios (1.32 and 1.26) (Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR19]\]. Based on the simulation results, the PBPK perpetrator model was considered to be qualified for assessing the DDI potential of elagolix as a perpetrator for CYP3A and P-gp substrates.Table 4PBPK model predictions: elagolix as a perpetratorVictim drugModel stageElagolix doseMean *C*~max~ ratioMean AUC~∞~ ratioPredictedObserved%PE (%)PredictedObserved%PE (%)MidazolamDevelopment150 mg QD0.750.818 (77)0.690.656 (46)Application200 mg BID0.51Not applicable0.44Not applicableDigoxin, day 1Development200 mg BID1.741.730.6 (42)1.221.328 (24)Digoxin, day 10200 mg BID1.731.711 (42)1.191.266 (21)Digoxin, day 1Application150 mg QD1.68Not applicable1.19Not applicableDigoxin, day 10150 mg QD1.731.19*AUC*~*∞*~ area under the curve from time zero to infinity, BID twice daily, *C*~max~ maximum concentration, *PBPK* physiologically based pharmacokinetic, *%PE* percentage prediction error (acceptance criteria), *QD* once dailyPBPK simulation trial design for midazolam: elagolix administered for 16 days, midazolam administered on day 14 as a single dosePBPK simulation trial design for digoxin: elagolix administered for 13 days, digoxin administered on days 1 and 10 as a single dose

PBPK Model Application: Prediction of the DDI Potential of Elagolix as a CYP3A4 and P-gp Perpetrator {#Sec11}
----------------------------------------------------------------------------------------------------

The final and verified PBPK model of elagolix was used to predict DDI with midazolam at the higher approved dose of 200 mg BID. The AUC of midazolam was predicted to decrease by 56%, while the *C*~max~ was predicted to decrease by 49% (Table [4](#Tab4){ref-type="table"}), following coadministration with elagolix 200 mg BID. The CYP3A4 induction simulation results enabled characterization of elagolix as a moderate inducer at the higher 200 mg BID dose, which was not evaluated in DDI trials, and informed the labeling language for coadministration with CYP3A substrates \[[@CR19]\].

Similarly, the final model was used to predict changes in the *C*~max~ and AUC of digoxin, following multiple 150 mg QD doses of elagolix. At 150 mg QD, the *C*~max~ and AUC of digoxin were predicted to increase by 68% and 19%, respectively, on day 1, while, on day 10, the *C*~max~ and AUC of digoxin were predicted to increase by 73% and 19%, respectively (Table [4](#Tab4){ref-type="table"}). These results indicated that elagolix inhibition of P-gp may not be dose- or time-dependent within the evaluated dose range.

Discussion {#Sec12}
==========

The PBPK model of elagolix was developed to mechanistically account for all of the known disposition mechanisms of elagolix (i.e. quantify the interplay between metabolism by CYP3A4, hepatic uptake by OATP1B1, and intestinal efflux by P-gp) and to support DDI dosing recommendations for the coadministration of elagolix with other drugs such as midazolam (CYP3A substrate) and digoxin (P-gp substrate). Elagolix has two approved dosages (150 mg QD and 200 mg BID) for the treatment of endometriosis, and DDI studies were conducted at either 150 mg QD or 200 mg BID for midazolam or digoxin, respectively.

The mechanisms involved in the disposition of elagolix were incorporated in the PBPK model using clinical DDI studies of elagolix with rifampin and ketoconazole. The interplay between the uptake transporter OATP1B1, efflux transporter P-gp, and drug-metabolizing enzyme CYP3A4 was captured using data from the elagolix--rifampin DDI study. Following a single dose, rifampin inhibits OATP1B1 and P-gp; however, following multiple doses, rifampin also induces CYP3A and P-gp \[[@CR4]\]. The relative contribution of OATP1B1 and P-gp in the transport of elagolix was optimized using clinical data following coadministration of a single dose of rifampin with elagolix. The AUC of elagolix was sensitive to the OATP1B1 maximal rate of transport (*J*~max~), and the optimized value of *J*~max~ was selected to match the observed elagolix AUC and *C*~max~ (electronic supplementary Fig. 1). The contribution of OATP1B1 and P-gp was fixed, and clinical data following multiple doses of rifampin coadministered with a single dose of elagolix were used to optimize the CYP3A4 and P-gp contributions. This approach of leveraging clinical DDI data following single and multiple doses of rifampin was recently used by Asaumi et al. to predict the complex DDIs of rifampin with glibenclamide \[[@CR20]\]. Given that the clinical DDI study of rifampin and elagolix was used to identify multiple parameters, the contribution of CYP3A4 and P-gp to the overall disposition of elagolix was independently verified using clinical data from the elagolix--ketoconazole DDI study to mitigate concerns regarding parameter identifiability (electronic supplementary Fig. 2). However, the OATP1B1 contribution could not be verified using an independent dataset since additional DDI studies of elagolix with an OATP1B1 inhibitor are not available. Nonetheless, the model-predicted exposures in the OATP1B1 phenotypes (extensive transporter, intermediate transporter, and poor transporter) matched the clinically observed exposures in subjects with matching OATP1B1 genotypes (data not shown), providing confidence in the assignment of the relative contribution of OATP1B1 in the active hepatic uptake of elagolix.

The ability of the model to capture the overall hepatic elimination of elagolix was further verified using clinical data of elagolix from the HI study. The HI population in the PBPK model in SimCYP^®^ version 15 accounts for most of the changes known to be associated with HI. The model reasonably predicted changes in the exposures of elagolix for Child--Pugh B and C patients, but overpredicted the exposures in Child--Pugh A patients. The differences in model predictions to the observed changes may be attributed to a combination of factors, such as a lack of information regarding the impact of HI on transporter expression, potential changes in the minor elimination pathways in the HI population that were not accounted for in the model, differences in the demographics of the study population, or the small sample size in the actual clinical study. The PBPK model predictions in the HI population are encouraging given that there is a growing interest in utilizing PBPK models to predict the impact of organ impairment on the PK of drugs. Morcos et al. used a PBPK model-based approach to provide recommendations regarding the study design of alectinib in patients with HI \[[@CR21]\], while Pilla Reddy et al. used the PBPK model of olaparib to predict the exposures in patients with HI following multiple doses \[[@CR22]\]. For obeticholic acid, a PBPK model was used to support regulatory recommendations regarding dose adjustment in HI patients. Taken together, the predictive ability of the elagolix PBPK model using external data from clinical pharmacology studies, including an HI study, indicates that the PBPK model performance of elagolix is robust for accurately predicting elagolix exposures at 150 mg QD and 200 mg BID.

While using the PBPK model to guide potential DDI risk assessment, a limitation of the model was the use of a single virtual population representative rather than a virtual population of subjects with varying intrinsic covariates. The population representative approach was selected to enable exploration of the implications of transporter--metabolism interplay on the PK of elagolix and the impact on coadministered CYP3A or P-gp substrates. In addition, the relative contribution of other minor metabolic pathways was incorporated in the PBPK model but were not verified in DDI studies with prototypical inhibitors. Future iterations of the model will investigate the influence of variability on elagolix PBPK simulations; however, this was beyond the scope of this application.

The key regulatory application of the PBPK model was to predict the DDI potential of elagolix at alternative doses that were not evaluated in the clinic (i.e. elagolix 200 mg BID with midazolam, or elagolix 150 mg QD with digoxin). The PBPK model was calibrated using the clinical data from DDI studies by optimizing the EC~50~ for CYP3A4 induction, and the K~i~ for P-gp inhibition. While optimized parameters were able to predict the clinically observed DDI potential, there is uncertainty associated with these parameter estimates given that data from DDI studies with one dose level of elagolix (i.e. 150 mg QD or 200 mg BID) were used for estimation. PBPK modeling results indicated that elagolix decreases midazolam exposures by approximately 50% following administration of elagolix 200 mg BID. These CYP3A4 induction simulation results enabled characterization of elagolix as a moderate inducer at the higher 200 mg BID dose, which was not evaluated in DDI trials.

The model was also used to characterize the dose-dependent effects of elagolix on P-gp after single and multiple doses. The predicted magnitude of DDIs at 150 mg QD is similar to the magnitude of DDIs clinically observed at 200 mg BID, suggesting that elagolix inhibition of P-gp may not be dose-dependent at this dose range of elagolix. This is anticipated given that the model-estimated *K*~i~ for P-gp was 0.5 µM, approximately 500-fold below the predicted intestinal elagolix concentration in the gastrointestinal lumen following administration of 150 or 200 mg of elagolix. A similar extent of P-gp inhibition was predicted on days 1 and 10 following elagolix administration, consistent with the short half-life and lack of accumulation of elagolix. Overall, the results from the PBPK model were used to inform the labeling language of elagolix for coadministration with CYP3A and P-gp substrates.

Conclusions {#Sec13}
===========

A PBPK model of elagolix that captures the absorption using a mechanistic model, the interplay between metabolism by CYP3A4 in the liver and gut, OATP1B1-mediated uptake in the liver, and intestinal and hepatic efflux via the P-gp transporter, along with the induction and inhibition of CYP3A4 and P-gp by elagolix, was developed and verified using in vitro and clinical PK/DDI data. The PBPK model was utilized to inform the DDI potential of elagolix as a perpetrator for CYP3A and P-gp substrates for doses at which clinical data were not available. Based on model predictions, elagolix is a weak to moderate inducer of CYP3A. Coadministration with elagolix may decrease plasma concentrations of drugs that are sensitive substrates of CYP3A. Elagolix is an inhibitor of the efflux transporter P-gp, and clinical monitoring for digoxin is recommended when coadministered with elagolix. This clinically verified PBPK model of elagolix may be used for future applications and regulatory submissions.
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